Chelsea Therapeutics, Inc. Reports Data Demonstrating Sustained Symptomatic Benefit of Northera in Neurogenic Orthostatic Hypotension Over 12-Month Treatment Period

CHARLOTTE, NC, Jan. 20, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period. The data also validate that the drug is safe and well tolerated following extended dosing up to two years.